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services. For the majority of UK children, length of stay (LOS) in hospital is brief and
rehydration alone is sufficient. More complex support is sometimes needed in
children with co-morbidities. OBJECTIVES: To compare the hospital burden (LOS
and cost), of children with RVGE and RSV alone, and vulnerable children with
co-morbidities. METHODS: Hospital data were obtained from the CHKS database
between April 1, 2001 and March 31, 2008, where patients, aged 5 years, were
admitted with a primary diagnosis of RVGE or RSV. Patients were categorised into
three groups. G1: a primary diagnosis of RVGE/RSV, G2: controls with a primary
diagnosis of eczema, G3: vulnerable children with a readmission for RVGE/RSV
following a prior admission, within 30 days, with a primary diagnosis of type 1
diabetes (T1D), cystic fibrosis, cancer, or epilepsy. RESULTS: A total of 102,270
patients were selected, group one n101,784 (mean age 0.2 years, LOS 1.9 days, cost
£595), group two n17,420, (mean age 1.1, LOS 1.7, cost £590), and group three
n486, (mean age 1.1, LOS 9.9, cost £3,477). Non-parametric tests showed that
mean age, and hospital LOS were significantly different between groups 1 and 2
(p0.001), while mean age, LOS, and cost were significantly different between
groups 1 and 3 (p0.001), and groups 2 and 3 (p0.001). When adjusted for age,
regression analysis showed that LOS was 5.2 times higher, and cost was 5.8 times
higher in group 3 than group 1. CONCLUSIONS: This study shows that vulnerable
children readmitted to hospital with RVGE/RSV, incur a greater LOS, and subse-
quent cost, compared to other groups. Universal rotavirus vaccination would sub-
stantially benefit vulnerable children through direct or indirect protection and
reduce the healthcare resource use resulting from hospital readmissions.
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OBJECTIVES: Estimating the costs associated with outbreaks and the prevention of
secondary cases of invasive meningococcal disease (IMD) is needed to understand
the true economic burden of IMD. We aimed to review the costs associated with
IMD outbreaks that occur globally. METHODS: Literature searches were conducted
in MEDLINE and EMBASE using medical subject headings and key words, such as
costs, outbreaks, and IMD. Studies were included if they reported the costs associ-
ated with IMD outbreaks and were written in English, French or Spanish. All costs
were converted to USD 2010. RESULTS: A total of 1672 citations were screened and
323 were potentially relevant. Nine studies fulfilled the inclusion criteria and in-
cluded IMD outbreaks with cost data from the US (n4), England, Canada, Guinea,
Burkina Faso and Australia (n1 each) between November 1992 and November
2006. Three outbreaks occurred among high school children, one among boys aged
3-6 years, another among individuals aged 18 years, and two occurred among all
ages. The majority were due to serogroup C (n7/9). The median number of in-
fected per outbreak was 8 (range: 3-2435). The attack rate ranged from 2 per
100,000 to 187 per 100,000, the hospitalization rate from 55.6% to 100%, and the
death rate from 0% to 26%. Containment strategies ranged from targeting all mem-
bers of the school where the outbreak occurred to targeting all students in the
community. The overall average cost per containment was $2,368,135 (USD 2010)
ranging from an average of $296,821 for small containment strategies (n3) to
$3,403,792 for large containment strategies (n6). CONCLUSIONS: IMG outbreaks
were associated with substantial costs. While numerous reports on outbreaks were
identified, few reported on the containment costs. More research in this area is
warranted, particularly to understand the economic value of new vaccines given
that the purpose of vaccination is to prevent potential outbreaks.
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OBJECTIVES: Endometriosis (the presence of endometrial-like tissue outside the
uterus) affects 10% of women of reproductive age and is associated with dysmen-
orrhoea, pain at ovulation, dyspareunia, abnormal bleeding, chronic pelvic pain,
fatigue, and infertility. This study aimed to calculate costs and health-related qual-
ity of life of women with endometriosis-associated symptoms treated in referral
centres. METHODS: A prospective, international, multi-centre questionnaire-
based survey measured costs and health-related quality of life in ambulatory care
and in 12 tertiary care centres in ten countries. The study enrolled women with a
diagnosis of endometriosis and with at least one centre-specific contact related to
endometriosis-associated symptoms in 2008. The main outcome measures in-
cluded health care costs, costs of productivity loss, total costs and quality-adjusted
life years. Predictors of costs were identified using regression analysis. RESULTS:
Data analysis of 909 women (63% response rate) demonstrated that the average
annual total cost per woman was €9,579 (95% CI €8,559-€10,599). Costs of produc-
tivity loss of €6298 per woman were double the health care costs (€3113 per
woman). Health care costs were mainly due to surgery (29%), monitoring tests (19%)
and hospitalization (18%). The cost of medication accounted for 10% of health care
costs. At a prevalence rate of 7%, the annual burden of endometriosis-associated
symptoms ranged from €0.8 billion in Denmark to €50 billion in the United States.
Endometriosis-associated symptoms generated 0.809 quality-adjusted life years
per woman. Decreased quality of life was the most important predictor of direct
health care and total costs. Costs were greater with increasing severity of endome-
triosis, presence of pelvic pain, presence of infertility, and higher number of years
since diagnosis. CONCLUSIONS: The economic burden associated with endome-
triosis is high and is similar to other chronic diseases (diabetes, Crohn’s disease,
rheumatoid arthritis). It arises predominantly from productivity loss, and is pre-
dicted by decreased quality of life.
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OBJECTIVES: To evaluate cost–effectiveness of pneumococcal vaccination with
10-valent pneumococcal non-typeable Haemophilus influenzae protein-D vaccine
(PHiD-CV) compared with 13-valent pneumococcal conjugate vaccine (PCV-13) and
no vaccination in The Kingdom of Saudi Arabia (KSA). METHODS: A steady state
model with a one-year time horizon was developed to project the impact of vacci-
nation on the incidence of pneumococcal and non-typeable Haemophilus Influenzae
(NTHi) infections in children aged 0-10 years. Data sources: Pneumococcal serotype
distribution is based on 176 invasive S. pneumoniae isolates collected in KSA hospi-
tals in 2005 to 2008. IPD, hospitalised pneumonia and acute otitis media (AOM)
disease incidence rates were based on a study from 12 hospitals in KSA, data from
Turkey and benchmarks with other countries. Vaccines coverage rates for IPD of
79.3 % and 83.9% for PHiD-CV and PCV-13, payer perspective, no herd protection
and a (31) vaccination schedule was assumed. RESULTS: PHiD-CV and PCV-13 are
projected to prevent more cases of invasive disease (724; 749 respectively) and
equal number of pneumonia hospitalizations (510; 510 respectively) compared to
no vaccination. PHiD-CV and PCV-13 are projected to prevent additional myringot-
omies (4783; 2365 respectively) and GP visits due to AOM (170,936; 84,518 respec-
tively) compared to no vaccination strategy. Vaccinating a birth cohort with
PHiD-CV or PCV-13 is expected to generate 8,966; 8,888 more QALYs compared to no
vaccination. At vaccine steady state cost-savings related to disease burden reduc-
tion are $14.1M and $7.6M for PHiD-CV and PCV-13 respectively compared with no
vaccination. Sensitivity analyses indicate that incidence rate of IPD has the biggest
impact on results. CONCLUSIONS: Incremental cost-effectiveness ratios indicate
that both vaccines are cost effective interventions. PHiD-CV dominates PCV-13
because it has a larger potential QALY gain and larger cost offset.
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OBJECTIVES: A 7-valent pneumococcal conjugate vaccine (PCV7) was launched as
a Category II vaccine requiring out-of-pocket payment in China in 2008. This study
evaluates the potential economic benefits of introducing a public financed City
Immunization Program (CIP) to pay for PCV7 from a payer perspective. METHODS:
A decision-analytic model was populated with local direct cost and seroprevalence
data from case records of 3 hospitals (1 Children’s Hospital; 2 Comprehensive Hos-
pitals) and literature to estimate the clinical and economic impact of no PCV7
vaccination, PCV7 Category II listing, and PCV7 CIP in the city of Shenzhen. Various
sources of data were used to estimate the primary statistics including age-specific
incidence/mortality of invasive pneumococcal disease (IPD), pneumonia and otitis
media, local patient demographics, and PCV7 efficacy from clinical trial data. The
indirect effect on unvaccinated populations was considered by estimating the re-
duction in adult IPD cases following PCV7 programs published overseas, and was
only applied in the CIP scenario where broad vaccine coverage could be achieved. A
discount rate of 5% was applied, and one-way sensitivity analyses were performed
as well. RESULTS: Under the current setting, the Category II vaccine PCV7 is not
cost-effective due to the private market unit price and low penetration rate. How-
ever, vaccination of 154,721 children under 2 years old from a public financed CIP in
Shenzhen would prevent 18 IPD, 5887 hospitalized pneumonia, 20020 outpatient
pneumonia, and 10669 otitis media cases if indirect effects are included, compared
to no vaccination program. From a payer perspective, a PCV7 CIP would achieve an
ICER of RMB61, 243 (USD9, 141) per QALY versus no vaccination, and dominant
versus Category II. CONCLUSIONS: Results from this study indicate a PCV7 CIP
would be a highly cost-effective intervention from a public payer’s perspective.
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OBJECTIVES: Attention deficit/hyperactivity disorder (ADHD) is a common psychi-
atric disorder with substantial clinical and economic implications. While psycho-
stimulants are first-line pharmacologic treatment, up to 30% of ADHD children
have suboptimal response to psychostimulants and require adjunctive therapy.
Our objective was to analyze the cost-effectiveness of adding an alpha-2A agonist,
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